Skip to main content

Vumon Side Effects

Generic name: teniposide

Medically reviewed by Last updated on Jan 30, 2024.

Note: This document contains side effect information about teniposide. Some dosage forms listed on this page may not apply to the brand name Vumon.

Applies to teniposide: intravenous solution.


Intravenous route (Solution)

Teniposide should be administered under the supervision of a qualified physician experienced in prescribing chemotherapy. Severe myelosuppression, resulting in infection or bleeding, may occur with teniposide. Hypersensitivity reactions, including anaphylaxis-like symptoms, may occur with initial dosing or with repeated exposure to teniposide. Epinephrine, with or without corticosteroids and antihistamines, has been used to treat hypersensitivity reactions.

Serious side effects of Vumon

Along with its needed effects, teniposide (the active ingredient contained in Vumon) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking teniposide:

More common

Check with your doctor as soon as possible if any of the following side effects occur while taking teniposide:

More common

Less common


Other side effects of Vumon

Some side effects of teniposide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

This medicine often causes a temporary loss of hair. After treatment with teniposide has ended, normal hair growth should return.

For Healthcare Professionals

Applies to teniposide: intravenous solution.


Very common (10% or more): Neutropenia (less than 2000 ANC/mcL) (95%), leukopenia (less than 3000 WBC/mcL) (89%), anemia (88%), thrombocytopenia (less than 100,000 plt/mcL) (85%), myelosuppression (75%)

Common (1% to 10%): Bleeding[Ref]


Common (1% to 10%): Hypersensitivity reaction (e.g., chills, fever, tachycardia, flushing, bronchospasm, dyspnea, rash, hypertension, hypotension)[Ref]


Common (1% to 10%): Hypotension[Ref]


Very common (10% or more): Infection (12%)[Ref]


Very common (10% or more): Mucositis (76%), diarrhea (33%), nausea/vomiting (29%)

Common (1% to 10%): Alopecia, rash[Ref]

Nervous system

Uncommon (0.1% to 1%): Neurotoxicity

Frequency not reported: Headache, asthenia[Ref]


Common (1% to 10%): Fever[Ref]


Frequency not reported: Confusion[Ref]


Uncommon (0.1% to 1%): Hepatic dysfunction[Ref]


Uncommon (0.1% to 1%): Renal dysfunction[Ref]


1. Product Information. Teniposide (teniposide). WG Critical Care. 2019.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.